 SAN DIEGO , Oct. 5, 2022 PRNewswire -- Poseida Therapeutics, Inc. Nasdaq: PSTX, a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that it will present a Trial in Progress poster at the upcoming Society for Immunotherapy of Cancer SITC Annual Meeting, being held in Boston and virtually from November 8 12, 2022. The poster presentation will highlight the trial design, dosing regimen, and study protocol for the Companys ongoing Phase 1 clinical trial of P-MUC1C-ALLO1. 